ArriVent BioPharma (AVBP) Other Gross PP&E Adjustments (2023 - 2026)
ArriVent BioPharma has reported Other Gross PP&E Adjustments over the past 4 years, most recently at -$451000.0 for Q1 2026.
- Quarterly results put Other Gross PP&E Adjustments at -$451000.0 for Q1 2026, up 14.58% from a year ago — trailing twelve months through Mar 2026 was -$451000.0 (up 14.58% YoY), and the annual figure for FY2025 was -$305000.0, up 51.43%.
- Other Gross PP&E Adjustments reached -$451000.0 in Q1 2026 per AVBP's latest filing, down from -$305000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$302000.0 in Q3 2025 and bottomed at -$801000.0 in Q2 2025.
- Median Other Gross PP&E Adjustments over the past 4 years was -$469500.0 (2024), compared with a mean of -$493000.0.
- Peak annual rise in Other Gross PP&E Adjustments hit 51.43% in 2025, while the deepest fall reached 159.22% in 2025.
- Over 4 years, Other Gross PP&E Adjustments stood at -$702000.0 in 2023, then rose by 10.54% to -$628000.0 in 2024, then skyrocketed by 51.43% to -$305000.0 in 2025, then crashed by 47.87% to -$451000.0 in 2026.
- Business Quant data shows Other Gross PP&E Adjustments for AVBP at -$451000.0 in Q1 2026, -$305000.0 in Q4 2025, and -$302000.0 in Q3 2025.